



29 July 2011

Resonance Health Ltd (ASX:RHT) Appendix 4C – 4th Quarter Cash Flow Report

Resonance Health Limited today released its fourth quarter cash flow report for the period ending 30 June 2011.

Cash at 30 June 2011 was \$1,503,000 representing a decrease of \$87,000 for the June 2011 quarter, compared with a decrease of \$84,000 in the previous quarter.

Cash receipts from customers were up 43% compared to the corresponding quarter in the previous year, despite the negative impact of the strengthening of the Australian dollar. Cash receipts were flat compared to the prior quarter.

The Company is eagerly awaiting the FDA decision on its Cardiac iron test, expected within the next few weeks. The Company is also preparing a submission to the FDA for its medical device to accurately assess fatty liver disease using MRI technology.

Research and development expenditure during the quarter was focussed on the development of technology to accurately assess the degree of liver fibrosis, using MRI. A clinical study is being conducted at the Austin Hospital in Melbourne in collaboration with Professor Angus, Medical Director of the Liver Transplant Unit. The study is ahead of schedule with 16 of the 30 patients now enrolled. The results of this study are expected in the first quarter 2012.

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Colin McDonald
Company Secretary
T: +61 8 9286 5300
E: colinm@ferriscan.com

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

30 June 2011

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	482	1,785
1.2 Payments for		
(a) staff costs	(293)	(1,303)
(b) advertising and marketing	(103)	(356)
(c) research and development	(177)	(483)
(d) leased assets	-	-
(e) other working capital	(87)	(277)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	-	80
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	-	-
1.7 Other Payments		
(a) consulting & professional services	(15)	(47)
(b) statutory & compliance	(1)	(131)
Other income- Grant income	109	109
Net operating cash flows	(85)	(623)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)	(85)	(623)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(2)	(8)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(2)	(8)
1.14	Total operating and investing cash flows	(87)	(631)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	-
	Net financing cash flows	-	-
	Net increase (decrease) in cash held	(87)	(631)
1.21	Cash at beginning of quarter/year to date	1,590	2,134
1.22	Exchange rate adjustments to item 1.20		
1.23	Cash at end of quarter	1,503	1,503

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	95
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

\$40K – Directors fees \$55K – Consulting fees

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	503	590
4.2 Deposits at call	-	-
4.3 Bank overdraft		
4.4 Other (provide details)		
- Term deposits	1,000	1,000
Total: cash at end of quarter (item 1.22)	1,503	1,590

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Colin McDonald
Company Secretary